How to Buy Mereo Biopharma Group Stock
Mereo Biopharma Group PLC
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally.
Mereo Biopharma Group stock last closed at $1.68, down 3.45% from the previous day, and has decreased 62.42% in one year. It has overperformed other stocks in the Biotechnology industry by 0.03 percentage points. Mereo Biopharma Group stock is currently +14.29% from its 52-week low of $1.47, and -66.53% from its 52-week high of $5.02.
There are currently 795.48M MREO shares outstanding. The market cap of MREO is $267.28M. In the past 24 hours, 744,000 MREO shares were traded.
How to Buy Mereo Biopharma Group Stock
Wondering how to invest in Mereo Biopharma Group stock? Here's how.
- Choose where to buy Mereo Biopharma Group stock: You need to choose a stock brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you decide where to buy Mereo Biopharma Group stock.
- Create your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit funds into your investment account: Choose your payment method and add your details.
- Evaluate Mereo Biopharma Group stock: The Mereo Biopharma Group ticker symbol is MREO. Is Mereo Biopharma Group stock a good investment? Should you buy shares of MREO? How do MREO's underlying business fundamentals look? Do top analysts think Mereo Biopharma Group is a good buy? Why has MREO's stock price moved recently? (Hint: Our stock market analysis tools can help you evaluate if MREO is a good stock to buy).
- Execute your MREO trade: Decide if you will purchase MREO shares at the current market price or use a limit order to purchase MREO shares at a specific price.
- Watch your investment in MREO: Create a watchlist to get the latest news on your new investment in Mereo Biopharma Group stock.
Step 1: Choose where to buy Mereo Biopharma Group stock
You will need a brokerage account in order to access the NASDAQ market and buy MREO shares.
Our favorite brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to world markets: From Technology to Financial Services, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Create your brokerage account
Now that you've chosen the right brokerage, it's time to fill out some personal details so you can buy MREO today.
How to Set Up a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal info to start a new trading account.
- Submit your data by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you've finished signing up on the best stock market app, you need to deposit funds:
Watch the video below for more details depositing money into your new investment account.
Step 4: Evaluate Mereo Biopharma Group stock
After you have decided on the best place to buy Mereo Biopharma Group stock, it's absolutely critical to evaluate their stock prior to investing, so you can understand the risk as well as the upside.
Mereo Biopharma Group quick stats
Mereo Biopharma Group Due Diligence Checks
WallStreetZen was designed to help average investors perform more accurate fundamental analysis.
You can see all of the due diligence checks on MREO's stock page.
Is MREO stock undervalued or overvalued?
You can use a variety of different financial metrics, analyses, models, and charts to gauge MREO's fair value.
Using relative valuations metrics:
- MREO may be overvalued based on its P/B ratio of 4.93x, relative to Biotechnology industry P/B ratio of 4.51x
You can do additional valuation research on MREO's stock here.
A look at MREO Cashflows and Balance Sheet
Signs that MREO is financially healthy:
- Total MREO debt is lower than 5 years ago, relative to shareholder equity.
- There are more short-term assets than short-term liabilities on the MREO balance sheet.
- MREO has $56.13M in cash and short term investments. This is enough to cover its annual cash burn of $32.94M.
- MREO has a low debt to equity ratio of 0.16.
- MREO has cash burn of 32939000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than long-term liabilities on the MREO balance sheet.
Signs that MREO is not financially healthy:
- MREO profit margin has gone down from -3,684.6% to -9,910% in the past year.
Is it a good time to buy MREO stock, according to analysts?
Out of 3 Equities analysts who give ratings on MREO, the consensus analyst rating on Mereo Biopharma Group is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they investment advice.
You can dive deeper into what analysts are projecting on the Mereo Biopharma Group stock forecast page.
MREO Trading Indicators
MREO Earnings
Last year, MREO revenue was $500.00k. In the last 4 year, MREO's revenue has gone up by -67.64% per year. This was slower than the Biotechnology industry average of 64.4%.
You can research MREO's earnings and revenue performance here.
Latest Insiders Trades at MREO
In the last year, executives and large shareholders at MREO have sold more shares than they have bought.
Christine Ann Fox, Chief Financial Officer of MREO, was the latest MREO insider to sell. They sold $80,865.92 worth of MREO shares on Sep 13, 2024.
Get more info about who owns MREO shares here.
Can I rely on MREO as an income stream?
No, Mereo Biopharma Group doesn't provide an income stream by paying out dividends.
What others are saying about MREO
One of the primary reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other traders have to say.
Step 5: Execute your MREO trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are generally fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular price limit, use a limit order.
Hit the Open Trade button and your broker will place your order.
If you require more help with investing in stocks on eToro, click the helpful video below:
Step 6: Watch your investment in MREO
Now that you own some shares in MREO, you'll want to stay up-to-date on your shares.
Start a watchlist to track the most important metrics related to your MREO stock.
MREO Feed
How to Buy Stock in Mereo Biopharma Group
To reiterate, here are the 6 steps to buy stock in Mereo Biopharma Group:
- Choose where to buy Mereo Biopharma Group stock
- Create your brokerage account
- Deposit funds into your investment account
- Evaluate Mereo Biopharma Group stock
- Execute your MREO trade
- Watch your investment in MREO
If you need a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to keep an eye on your investment in Mereo Biopharma Group, create a watchlist today.
Trending "How To" Guides
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.